These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15920908)

  • 21. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
    Yu ML; Dai CY; Lee LP; Hsieh MY; Hou NJ; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Antivir Ther; 2006; 11(8):1015-9. PubMed ID: 17302371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
    Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
    Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature.
    Hurst EA; Mauro T
    Arch Dermatol; 2005 Jul; 141(7):865-8. PubMed ID: 16027302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
    Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
    Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
    Jara P; Hierro L; de la Vega A; Díaz C; Camarena C; Frauca E; Miños-Bartolo G; Díez-Dorado R; de Guevara CL; Larrauri J; Rueda M
    Pediatr Infect Dis J; 2008 Feb; 27(2):142-8. PubMed ID: 18174875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.
    Chuang WL; Dai CY; Chen SC; Lee LP; Lin ZY; Hsieh MY; Wang LY; Yu ML; Chang WY
    Liver Int; 2004 Dec; 24(6):595-602. PubMed ID: 15566510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hepatitis C.
    Heathcote J; Main J
    J Viral Hepat; 2005 May; 12(3):223-35. PubMed ID: 15850462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
    Tromm A; Greving I; Griga T; Mankel K; Hüppe D
    Z Gastroenterol; 2000 Feb; 38(2):159-64. PubMed ID: 10721171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Giannini EG; Basso M; Savarino V; Picciotto A
    Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review.
    Omazzi B; Prada A; Borroni G; Sacrini F
    Hepatol Res; 2012 Dec; 42(12):1248-51. PubMed ID: 23181541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
    Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy.
    Gheorghe L; Cotruta B; Trifu V; Cotruta C; Becheanu G; Gheorghe C
    Int J Dermatol; 2008 Sep; 47(9):957-9. PubMed ID: 18937663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
    Al-Traif I; Handoo FA; Al-Jumah A; Al-Nasser M
    Saudi Med J; 2004 Dec; 25(12):1935-8. PubMed ID: 15711670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
    González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
    Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.
    Narayanan Menon KV; Poterucha JJ; El-Amin OM; Burgart LJ; Kremers WK; Rosen CB; Wiesner RH; Charlton M
    Liver Transpl; 2002 Jul; 8(7):623-9. PubMed ID: 12089717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
    Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.